World Health Organization site
Skip Navigation Links

Main
Note: This record shows only 22 elements of the WHO Trial Registration Data Set. To view changes that have been made to the source record, or for additional information about this trial, click on the URL below to go to the source record in the primary register.
Register: ClinicalTrials.gov
Last refreshed on: 19 February 2015
Main ID:  NCT00606749
Date of registration: 22/01/2008
Prospective Registration: No
Primary sponsor: Kemia, Inc
Public title: Use of KC706 for the Treatment of Pemphigus Vulgaris
Scientific title: A Phase 2 Open-Label Uncontrolled Pilot Study of KC706 in Patients With Stable, Active Pemphigus Vulgaris
Date of first enrolment: November 2007
Target sample size: 20
Recruitment status: Completed
URL:  http://clinicaltrials.gov/show/NCT00606749
Study type:  Interventional
Study design:  Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment  
Phase:  Phase 2
Countries of recruitment
United States
Contacts
Name:     Victoria Werth, MD
Address: 
Telephone:
Email:
Affiliation:  University of Pennsylvania
Name:     Bruce Strober, MD
Address: 
Telephone:
Email:
Affiliation:  NYU MEDICAL CENTER
Name:     Michael Kolodney, MD
Address: 
Telephone:
Email:
Affiliation:  University of California, Los Angeles
Name:     David Rubenstein, MD, PhD
Address: 
Telephone:
Email:
Affiliation:  University of North Carolina, Chapel Hill
Name:     Francisco Kerdel, MD
Address: 
Telephone:
Email:
Affiliation:  Florida Academic Dermatology Centers
Name:     Neil Korman, MD
Address: 
Telephone:
Email:
Affiliation:  University Hospital Case Medical Center
Name:     Amit Pandya, MD
Address: 
Telephone:
Email:
Affiliation:  University of Texas Southwestern Medical Center
Key inclusion & exclusion criteria

Inclusion Criteria:

- At least 18 years of age;

- Diagnosis of pemphigus vulgaris

- Patients must be taking and require either corticosteroid therapy or
immunosuppressive therapy or both;

- Immunosuppressive therapy, if any,should have been administered at a stable dose for
at least 60 days prior to the Baseline Visit and be well-tolerated, without the
expectation that there will be a need to increase that dose during the next 30 days;

- Corticosteroids, if any, should have been administered at a stable dose for at least
30 days prior to the Baseline Visit without expectation that there will be a need to
increase that dose during the next 30 days;

- Patients should have active PV skin, scalp or mucosal lesions that meet at least one
of the following criteria at the Baseline Visit:

- > 3 new lesions/week every week in the previous 3 weeks (skin, scalp, and/or
mucosal), with healing occurring at a rate to match the appearance of new
lesions; or

- At least 3 active, established lesions with a Pemphigus Lesion Score of at least
2; skin or scalp lesions must be = 5mm in diameter to qualify; there is no size
requirement for mucosal lesions; or,

- 1 large active established skin, scalp, or mucosal lesion > 10 mm;

- Accessibility to veins suitable for venipuncture;

- Patients must be cooperative, able to read, understand and give informed consent, and
able to adhere to the study visit schedule and protocol requirements; and,

- Patients must be willing to follow adequate contraceptive measures during the study
(both sexes).

Exclusion Criteria:

- Any history of opportunistic infections within 3 months prior to receiving study
drug;

- Infection with HIV;

- Past or present diagnosis of hepatitis confirmed by serology or elevated hepatic
enzymes;

- History of alcoholic liver disease or cirrhosis;

- Clinically significant concurrent medical disease or laboratory abnormalities
evidenced by one or more of the following:

- Hepatobiliary AST or ALT = 1.5 × upper limit of normal (ULN);alkaline
phosphatase = 1.5 × ULN; or, total bilirubin > 90% of the ULN;

- Renal serum creatinine > 1.5 mg/dL; or, significant proteinuria > 2+ on urinary
dip test;

- Hematologic hemoglobin < 11 mg/dL; leukocytes < 3.5 × 109/L; neutrophils < 1.5 ×
109/L; or, platelets < 100 × 109/L;

- Presence or history of malignancy;

- Uncontrolled diabetes (defined as diabetes requiring hospitalization or emergency
care in the 3 months prior to first dose of study drug);

- History or suspicion of Gilbert's syndrome;

- Significant blood loss (> 500 mL) within 28 days prior to receipt of study drug;

- Use of an investigational drug within 30 days of screening, or longer if that drug is
expected to have long-acting effects (e.g., modulation of B-cell activity);

- Use of Rituximab within the past 6 months;

- Use of intravenous IgG within the past 3 months,

- Current or recent history (within 12 months of screening) of drug or substance abuse,
including alcohol;

- Known or suspected pregnancy; nursing mothers;

- Clinically significant abnormality on the screening physical examination performed at
the Baseline Visit, laboratory testing, vital signs or electrocardiogram suggestive
of significant unstable medical condition other than the disease under study;

- Condition which, in the opinion of the Investigator, could interfere with
participation in the study or would put the patient at unacceptable risk;

- History of noncompliance with medical regimens.



Age minimum: 18 Years
Age maximum: N/A
Gender: Both
Health Condition(s) or Problem(s) studied
Pemphigus Vulgaris
Intervention(s)
Drug: KC706
Primary Outcome(s)
To evaluate the ability of KC706 to prevent the appearance of new lesions and heal existing lesions, while maintaining stable doses of corticosteroids and/or immunosuppressants in patients with pemphigus vulgaris. [Time Frame: 16 weeks]
Secondary Outcome(s)
Evaluate the safety of KC706 in patients with PV and to assess plasma levels of KC706 with once daily dosing. [Time Frame: 16 weeks]
Secondary ID(s)
KC706-C08
Source(s) of Monetary Support
Please refer to primary and secondary sponsors
Secondary Sponsor(s)
Ethics review
Results
Results available:
Date Posted:
Date Completed:
URL:
Disclaimer: Trials posted on this search portal are not endorsed by WHO, but are provided as a service to our users. In no event shall the World Health Organization be liable for any damages arising from the use of the information linked to in this section. None of the information obtained through use of the search portal should in any way be used in clinical care without consulting a physician or licensed health professional. WHO is not responsible for the accuracy, completeness and/or use made of the content displayed for any trial record.
Copyright - World Health Organization - Version 3.6 - Version history